ProQR Therapeutics’ (PRQR) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of ProQR Therapeutics (NASDAQ:PRQR) in a research note published on Thursday morning,Benzinga reports. Chardan Capital currently has a $4.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently weighed in on the stock. HC Wainwright increased their price objective on shares of ProQR Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. StockNews.com cut ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Finally, Raymond James raised ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the company from $6.00 to $14.00 in a research note on Tuesday, October 29th. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $7.60.

ProQR Therapeutics Price Performance

NASDAQ PRQR opened at $2.83 on Thursday. The stock has a market capitalization of $231.15 million, a P/E ratio of -8.84 and a beta of 0.24. The firm’s 50-day moving average is $3.40 and its two-hundred day moving average is $2.40. ProQR Therapeutics has a 12 month low of $1.61 and a 12 month high of $4.62.

Institutional Investors Weigh In On ProQR Therapeutics

Large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its stake in shares of ProQR Therapeutics by 14.2% in the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 7,300 shares in the last quarter. OneDigital Investment Advisors LLC raised its stake in shares of ProQR Therapeutics by 37.0% in the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 15,550 shares in the last quarter. Finally, Privium Fund Management B.V. boosted its holdings in ProQR Therapeutics by 0.9% in the third quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after purchasing an additional 51,663 shares during the period. 32.65% of the stock is owned by hedge funds and other institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).